PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15526247-3	2004	AIMS: To investigate the relationship between the levels of B-type natriuretic peptide (BNP) and A-type natriuretic peptide (ANP) and the clinical and functional parameters of CHF in outpatients with CHF at baseline, compared with normal healthy controls; to find out the differences in a randomised controlled trial between patients treated with an angiotensin-converting enzyme (ACE) inhibitor, captopril, or an angiotensin receptor blocker (ARB), irbesartan.	Irbesartan	450-460	natriuretic peptide B	Homo sapiens	60-86	
30356256-4	2018	This study aimed to investigate the protective role of a pre-treatment (10 and 100 muM) with irbesartan on injury induced by 24 h of hypoxia in HL-1 cardiomyocytes; in particular, we have analyzed the natriuretic peptide (BNP) expression, a biomarker able to modulate inflammatory reaction to cardiac injury and some markers involved in oxidative stress and inflammation.	Irbesartan	93-103	natriuretic peptide B	Homo sapiens	222-225	
30356256-8	2018	Our findings also showed that BNP induced by ischemia was significantly and in a concentration-dependent manner reduced by irbesartan.	Irbesartan	123-133	natriuretic peptide B	Homo sapiens	30-33